GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes

Clinical trial NCT00280865 · COMPLETED

Trial details

NCT number: NCT00280865
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Type 2 Diabetes

Start date: 2002-04-01
Enrollment: 500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.